This document is a publication of a European patent application (EP2024197271A1) related to targeting lysosomal lipid in Alzheimer's disease. It includes IPC classifications and designated states but notes that the inventor designation has not yet been filed.

As this is a patent publication, it does not impose direct compliance obligations on regulated entities. However, it may be of interest to pharmaceutical and biotechnology companies involved in Alzheimer's disease research and development, as well as medical device manufacturers exploring diagnostic or therapeutic tools in this field. Compliance officers should note this publication for its relevance to ongoing R&D and potential future regulatory pathways for related products.